< Key Hightlight >

MARKET OUTLOOK 

Europe’s Alzheimer’s disease therapeutics and diagnostics market is anticipated to exhibit growth with a CAGR of 5.75% during the projected years from 2021 to 2028. The United Kingdom, Spain, France, Italy, Germany, Russia, and Rest of Europe together form the market in this region.

The market in Europe is driven mainly by the rising mortality rate due to Alzheimer’s disease and government efforts, such as the conferences and meetings to promote awareness about the condition. Several research studies are being conducted in the region in the arena of AD therapeutics and diagnostics. For instance, in April 2021, Thomas Zilli (from Switzerland’s Geneva University Hospital) began studying the effect of low-dose radiotherapy on brain amyloidosis for the treatment of Alzheimer’s disease. Such initiatives are expected to aid the regional market’s growth.

In 2019, 12.499 million people were aged 65 years and over in the UK. This number is projected to reach 15.166 million people by 2030. As per the Alzheimer’s Europe 2019 report, in 2018, 1.56% of the population was affected by dementia. And, by 2050, 2.67% of the population is expected to be affected by this condition. The elderly are more prone to developing diseases like dementia and Alzheimer’s. This is expected to bolster the demand for Alzheimer’s diseases therapeutics and diagnostics in the United Kingdom, which, in turn, will aid the market growth.

COMPETITIVE OUTLOOK

The leading competitors in the Alzheimer’s disease therapeutics and diagnostics market include PeopleBio Co, Pfizer Inc, GE Healthcare, Novartis AG, Lupin Limited, F Hoffmann La Roche, Sun Pharmaceuticals Industries Ltd, Teva Pharmaceutical Industries Limited, Eisai Co Ltd, and Eli Lilly & Company.